Invesco Ltd. Buys 468,173 Shares of Zoetis Inc. $ZTS

Invesco Ltd. boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 17.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,223,761 shares of the company’s stock after buying an additional 468,173 shares during the quarter. Invesco Ltd. owned approximately 0.73% of Zoetis worth $502,745,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. 1832 Asset Management L.P. raised its holdings in Zoetis by 41.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 32,164 shares of the company’s stock worth $5,016,000 after purchasing an additional 9,472 shares during the last quarter. CW Advisors LLC raised its stake in shares of Zoetis by 0.9% during the second quarter. CW Advisors LLC now owns 86,506 shares of the company’s stock worth $13,489,000 after buying an additional 767 shares during the last quarter. PharVision Advisers LLC bought a new position in Zoetis in the second quarter valued at approximately $327,000. Peloton Wealth Strategists raised its position in shares of Zoetis by 3.3% during the 2nd quarter. Peloton Wealth Strategists now owns 12,904 shares of the company’s stock valued at $2,012,000 after acquiring an additional 407 shares during the last quarter. Finally, Groupe la Francaise boosted its position in shares of Zoetis by 111.8% in the 2nd quarter. Groupe la Francaise now owns 40,802 shares of the company’s stock worth $6,337,000 after purchasing an additional 21,534 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday. Stifel Nicolaus decreased their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Morgan Stanley lowered their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Finally, Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Stock Down 1.8%

NYSE:ZTS opened at $120.33 on Friday. The company has a market cap of $53.03 billion, a PE ratio of 20.26, a PEG ratio of 2.54 and a beta of 0.97. The stock has a 50-day simple moving average of $134.27 and a 200 day simple moving average of $148.09. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the business earned $1.58 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.